Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

Fortune_Finder Jul. 15 at 10:36 AM

$ENSC shares yes but the bigger green gains will always be made on the ENSCW warrants for the win win!

0 · Reply

ourscooby Jul. 14 at 12:05 PM

$ENSC price action and volume changes tell a tale. Especially when 3 different activities occur back to back to back. That's what happened here last week. Be Ready

0 · Reply

Dachshundtrader Jul. 14 at 11:12 AM

$ASMB What ChatGPT says 😅 Opinions? $ASMB has 3 clinical shots, $GILD lurking, $90M in cash, and a float tighter than $ENSC before it went parabolic. No eyes, no hype — yet. But when real volume shows up, this isn’t going up... it’s going airborne. Think $PRST. Think $BRTX. Then squint.

0 · Reply

HeisenbergCT Jul. 12 at 11:51 AM

$ENSC You guys are reading tea leaves; reading into price action and seeing signals and signs that exist only in your mind. This is about releasing significant clinical data on Phase 3 trials (of which is still delayed), and *significant* data on the progress of phase 1b (pipeline 2 nowhere near complete), nothing more and nothing less. Keep it simple. "Painweek" and other symposiums or conventions, have never ever moved this stock since it went public - never! Nor any podcast Lynn has done - not one time in any way! If the company chooses to release significant data during one of these events it would be unprecedented and highly unusual. good luck.

1 · Reply

besureman Jul. 11 at 4:05 PM

$ENSC just a mindless observation: the last 2 times (current included) that this has flirted with going below $2, it has had a quick recovery in the proceeding trading days. Hopefully there's some good news on deck and some bigger players wanted to load the boat at the $2 level.

1 · Reply

EnsysceBiosciences Jul. 11 at 10:16 AM

$ENSC Chronic pain doesn’t just affect the body - it reshapes daily life, relationships, and mental health. “At 52 I can no longer work and my activities are dictated by my pain levels.” “Isolation… not having a normal life and feeling like there's no future.” Our clinical programs at Ensysce Biosciences are focused on developing tamper-resistant, overdose-protected pain relief that addresses this reality, helping patients without fueling the opioid crisis. We believe better pain care must include better safety. #ENSC #MPAR #ChronicPainAwareness *Quotes and graphic courtesy of Pain Alliance Europe.

2 · Reply

Tbags19 Jul. 9 at 4:19 PM

$ENSC sold my warrants, dont think we'll get back to 37,000 stock price any time soon lol

0 · Reply

HeisenbergCT Jul. 9 at 12:12 PM

$ENSC lottery ticket with slightly better odds of winning

1 · Reply

Rhino_S Jul. 9 at 11:44 AM

$ENSC how does MPAR work and when will it be ready if successful?

1 · Reply

EnsysceBiosciences Jul. 9 at 11:35 AM

$ENSC Save The Date: PAINWeek is the largest pain conference in the world where experts meet to share knowledge to enhance patient care. The Ensysce-sponsored symposium ‘Pain Management, RE-Invented: A New Era for Analgesia' will take place in Las Vegas on September 3rd, 2025. Three world-renowned experts will discuss a range of topics to help practitioners achieve optimal results when treating severe pain. The confirmed speakers for the Ensysce symposium are: - Dr. Jeff Gudin, University of Miami Pain Center - Dr. Todd Bertoch, Chief Medical Officer, Pain Research at CenExel JBR - Dr. William Schmidt, Chief Medical Officer, Ensysce Biosciences #PAINWeek2025 #PainManagement #EnsysceBiosciences #PainReinvented #ENSC

0 · Reply

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 4 weeks ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 5 weeks ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 2 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 12, 2025, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Apr 24, 2025, 4:15 PM EDT - 2 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 5:11 PM EDT - 2 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 4:41 PM EDT - 2 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 15, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 4 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 8:00 AM EST - 4 months ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 4 months ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 5 months ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 6 months ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 8, 2025, 8:00 AM EST - 6 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 23, 2024, 8:00 AM EST - 7 months ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 10, 2024, 8:00 AM EST - 7 months ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 4, 2024, 8:00 AM EST - 7 months ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 3, 2024, 4:15 PM EST - 7 months ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Nov 26, 2024, 8:00 AM EST - 8 months ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 12, 2024, 4:15 PM EST - 8 months ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 8:00 AM EST - 8 months ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Oct 8, 2024, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 2, 2024, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Sep 27, 2024, 4:30 PM EDT - 10 months ago

Ensysce Biosciences Receives Notice from Nasdaq

Sep 24, 2024, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 19, 2024, 7:00 AM EDT - 10 months ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 13, 2024, 8:00 AM EDT - 10 months ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Aug 29, 2024, 8:00 AM EDT - 11 months ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 27, 2024, 2:30 PM EDT - 11 months ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Aug 23, 2024, 8:00 AM EDT - 11 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Aug 14, 2024, 4:15 PM EDT - 11 months ago

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 8:25 AM EDT - 1 year ago

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Mid-Year 2024 Update

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Jun 6, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

May 20, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Reports First Quarter 2024 Financial Results

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

Apr 19, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

Fortune_Finder Jul. 15 at 10:36 AM

$ENSC shares yes but the bigger green gains will always be made on the ENSCW warrants for the win win!

0 · Reply

ourscooby Jul. 14 at 12:05 PM

$ENSC price action and volume changes tell a tale. Especially when 3 different activities occur back to back to back. That's what happened here last week. Be Ready

0 · Reply

Dachshundtrader Jul. 14 at 11:12 AM

0 · Reply

HeisenbergCT Jul. 12 at 11:51 AM

1 · Reply

besureman Jul. 11 at 4:05 PM

1 · Reply

EnsysceBiosciences Jul. 11 at 10:16 AM

2 · Reply

Tbags19 Jul. 9 at 4:19 PM

$ENSC sold my warrants, dont think we'll get back to 37,000 stock price any time soon lol

0 · Reply

HeisenbergCT Jul. 9 at 12:12 PM

$ENSC lottery ticket with slightly better odds of winning

1 · Reply

Rhino_S Jul. 9 at 11:44 AM

$ENSC how does MPAR work and when will it be ready if successful?

1 · Reply

EnsysceBiosciences Jul. 9 at 11:35 AM

0 · Reply

GJ_Rockabilt Jul. 8 at 1:23 AM

$HCTI Traders and Investors: What can a Blank Reverse Split do? Who is ready for Stock Price swings to the magnitude of Mullen Automotive, $MULN, or Ensysce BioSciences, $ENSC?

1 · Reply

EnsysceBiosciences Jul. 7 at 12:11 PM

$ENSC Looking Back at Q1 & Q2 2025: A Strategic Launchpad for Ensysce Biosciences (Part 1/2, post continues in the comments) The first half of 2025 laid the groundwork for what could be a transformational year in overdose protection and abuse deterrence. Here’s why Q1 and Q2 were so pivotal: • Q1 Financial & R&D Discipline: Reported first quarter 2025 results on May 13, highlighting disciplined cash burn and sustained R&D investments in PF614‑MPAR and PF614 to advance overdose protection and abuse deterrence technologies. • Secured Continued NIDA Support: On June 4, 2025, Ensysce received a $5.3 million award from the National Institute on Drug Abuse to finalize PF614‑MPAR formulation and accelerate its path to commercialization.

3 · Reply

Mateine Jul. 3 at 8:52 PM

$ENSC Investors $ENSC Quick question for the team 👇 We’ve noticed that most trading days see modest volume (20k–100k shares), but once in a while volume spikes into the millions — sometimes even higher than the reported float. Just curious: are there known catalysts or technical reasons behind these big surges? 👀 Not pointing fingers — just trying to better understand the trading dynamics as we all follow the company’s progress closely. Appreciate any insights! #ENSC #InvestorQuestions #VolumeSpike

2 · Reply

mrsparex Jul. 3 at 5:02 PM

$ENSC 🤥 Yall remember posters saying we'd be under a dollar by Summer❓ ⛱️ 😂 Summer started about two weeks ago❗

0 · Reply

Ensysce_Responder Jul. 3 at 8:02 AM

$ENSC 💬 Shareholders, we welcome your questions. We understand how important clear communication is, especially as we advance our programs and work toward key milestones. If you have questions about our development progress, regulatory path, or strategic plans, we encourage you to ask. Well address what we can based on public information and appreciate your engagement as part of the Ensysce shareholder community. Feel free to share your questions below, were listening. #ENSC #InvestorEngagement #PipelineProgress #ShareholderUpdates

2 · Reply

EnsysceBiosciences Jul. 2 at 1:58 PM

$ENSC Ensysce isn't just reformulating painkillers. Its reengineering how pain relief is delivered, replacing the peaks and crashes of standard opioids with stable, controlled release, combined with a built-in “switch” to help prevent overdose. We believe this next-gen platform isn't just safer, it could reduce healthcare costs, and change how the system treats pain.

1 · Reply

Love_To_Learn Jul. 1 at 8:20 PM

$ENSC $GNLN moving things along !

0 · Reply

EnsysceBiosciences Jul. 1 at 10:11 AM

$ENSC A recent quote from Dr. Lynn Kirkpatrick featured in the latest press release: Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2 #OpioidSafety #AddictionPrevention #OverdoseProtection

1 · Reply

Ensysce_Responder Jun. 30 at 2:19 PM

$ENSC Welcome to the official Ensysce Biosciences Responder account! Were here to provide accurate, timely answers to shareholder questions and keep communication transparent. Ask us anything, our team is listening. $ENSC #InvestorRelations #ShareholderCommunication

1 · Reply

EnsysceBiosciences Jun. 29 at 7:13 AM

$ENSC For patients suffering from severe pain who require opioid-level relief, our product/s are the next generation of opioid analgesics. ✔️ Abuse deterrence built into the chemistry ✔️ Overdose protection activated if over-consumed ✔️ Designed to meet the highest safety standards from day one #PainManagement #Biotech #PublicHealth

0 · Reply

Love_To_Learn Jun. 27 at 8:46 PM

$ENSC $GNLN will lso affect $VERO n bind where they travelled from b4 the pop

1 · Reply

Love_To_Learn Jun. 27 at 8:46 PM

$ENSC picked up that 2.06 from amix 2.06/2.07 bullet in chamber seqeunce using the ask 2.27* stretching the field then using your 3.49 3.38 april 24 n 25th for $GNLN

0 · Reply

Market Cap	5.12M
Revenue (ttm)	5.21M
Net Income (ttm)	-7.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-153.36%
Debt to Equity Ratio	0.00

Volume	216,400
Avg Vol	234,360
Day's Range	N/A - N/A
Shares Out	2.37M
Stochastic %K	53%
Beta	0.98
Analysts	Strong Buy
Price Target	$18.45